Alcon directors protest Novartis takeover bid

pharmafile | January 6, 2010 | News story | Research and Development, Sales and Marketing Alcon, Novartis 

An independent committee of directors of Alcon has expressed its disappointment with the recent takeover bid from Novartis, saying the Swiss drugmaker is trying to circumvent protections for minority shareholders.

Novartis aims to buy the rest of eye care group Alcon for just under $40 billion to reduce its reliance on prescription drugs, but is offering minority shareholders a worse deal than major owner Nestle.

The Swiss company’s offer to minority Alcon shareholders of 2.8 Novartis shares for each of their shares in the eye care group is currently worth $147, well below the $180 agreed with Nestle.

Swiss law would allow Novartis to force through the deal once it obtains a majority from Nestle, as mergers require approval of two thirds of shareholders and a simple board majority.

“Novartis has taken the gloves off and claims that since this is not a tender offer, minority owners have no option but to approve the deal, since Novartis will soon control Alcon’s board,” Kepler Capital Markets analyst Tero Weckroth told Reuters.

While Alcon is listed on the New York Stock Exchange it is incorporated in Switzerland and thus bound by law there. This means once Novartis completes its deal for Nestle’s majority stake a legal challenge to the takeover would be the only recourse left to Alcon’s minority shareholders.

Alcon said on Monday an independent director committee believed the company had established certain important protections for its minority shareholders against a coercive takeover bid.

“Novartis appears to be attempting to circumvent the minority protection principles … by claiming that the Alcon minority shareholders are neither accorded minority protections under the Swiss Takeover Code nor the rules under the NYSE,” the Alcon directors committee said in a statement.

Related Content

Novartis shares new data about Fabhalta for IgAN treatment

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …

chuttersnap-oijvdm3zx4i-unsplash

Novartis shares new data for Zolgensma in children with SMA

Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …

Novartis to acquire MorphoSys AG for €2.7bn

Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, …

Latest content